antibody

MSD to Buy B-Cell Depletion Therapy from Curon

Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.

CMC Biologics Hikes Capacity in Denmark

Shire Takes Novimmune’s Blood Therapy Rights

Merck Takes Antibody License from Teijin

MRC Licenses Hepatitis C Antibody to China

Mundipharma to Launch Biosimilar Truxima in Europe

Merck Settles Keytruda Patent Disputes

MedImmune and Abpro Spin Out Antibody Firm

Topics • Strategy

Leaving the Patent Cliff Behind

Top-Feature

Concept Heidelberg

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

JMP Statistical Discovery / SAS Institute GmbH

From Data to Decisions: Digital Tools Reshaping the Chemical and Life Sciences Landscape

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Europe’s Biotech Inflection Point

Nova-Institut GmbH

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Brenntag Downsizes Management Board, Retains Both Divisions

Leading Transformation

Easyfairs Deutschland GmbH

Industry Kick-Off with Signal Effect: More Than 310 Exhibitors expected at maintenance and PUMPS & VALVES 2026

Dow Chemical Company

Anchored in Sustainability

CHEManager International c/o Wiley-VCH GmbH

API Manufacturing

Easyfairs Deutschland GmbH

Leading the way. Driving results.

Interview

Leading Transformation

The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

EvaluatePharma